Compare ICCC & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCC | RFL |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.1M | 92.6M |
| IPO Year | 1995 | 2017 |
| Metric | ICCC | RFL |
|---|---|---|
| Price | $9.91 | $2.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.5K | ★ 92.9K |
| Earning Date | 05-15-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | 28.28 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $26,493,169.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.44 | ★ N/A |
| Revenue Growth | ★ 51.64 | 43.96 |
| 52 Week Low | $4.52 | $1.12 |
| 52 Week High | $12.10 | $3.96 |
| Indicator | ICCC | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 62.84 |
| Support Level | $9.36 | $1.21 |
| Resistance Level | $10.75 | $3.96 |
| Average True Range (ATR) | 0.45 | 0.17 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 29.56 | 82.67 |
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.